The combination of GO and chemotherapy has been shown to improve RFS and OS, especially in patients with favorable-risk core-binding factor AML and intermediate-risk disease, including NPM1-mutated AML, but not in patients with adverse-risk disease, likely related to the high levels of CD33 expression [64,65,66]. This evidence concerns the gene CD33 and acute myeloid leukemia.